
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
11 January 2019
Myelofibrosis: Finding new ways to treat patients
Dr Edwin Chen, University of Leeds and John Goldman Fellow
17 October 2022
New campaign launches for the forgotten 500,000 families
Patient groups, charities and clinicians unite to raise awareness of half a million vulnerable people, many of whose lives have never returned to normal after the Covid-19 lockdown. A new…
20 October 2023
Emerging leaders accolade for former Leukaemia UK John Goldman Fellows
Former Leukaemia UK John Goldman Fellows, Dr Matthew Blunt, University of Southampton and Dr Konstantinos Tzelepis, University of Cambridge have been recognised as ‘Emerging Leaders in Leukaemia’ by the major…
8 November 2022
Leukaemia UK announces John Goldman Fellows for 2022
Leukaemia UK has awarded their prestigious John Goldman Fellow research grants to four outstanding early-career researchers seeking to advance our understanding of and ability to treat blood cancer. Leukaemia UK…